Autologous Immunotherapy as a Novel Treatment for Bladder Cancer by Schumacher, Martin C. & Sherif, Amir M.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 5
Autologous Immunotherapy as a
Novel Treatment for Bladder Cancer
Martin C. Schumacher and Amir M. Sherif
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54226
1. Introduction
Cancer is fundamentally a disease with failure in regulation in tissue growth and the risk of
developing cancer increases with age. The armamentarium in treating cancer is mainly
threefold: surgical resection of the tumor, radiation therapy and cytotoxic drugs. For blad‐
der cancer, results from contemporary radical cystectomy series with pelvic lymph node dis‐
section for T2-4 NX M0 transitional cell carcinoma (TCC) provides accurate pathologic
staging of the primary tumor and lymph nodes, and due to increasing expertise with the dif‐
ferent types of urinary diversions durable preservation of quality of life. However, the 5-
year survival rate for all patients with pT2 tumors is approximately 50 – 80%, and for those
with negative lymph nodes 64 – 86% (Stein, Lieskovsky et al. 2001) (Shariat, Karakiewicz et
al. 2006) (Hautmann, de Petriconi et al.). In contrast, the 5-year survival rates for locally ad‐
vanced cancers, pT3 and pT4, in contemporary cystectomy series range from 22 – 58%. The
presence of pathologically proven lymph node metastases at radical cystectomy is associat‐
ed with a poor outcome with a 5-year survival of 30%.
After more than 30 years of clinically research in bladder cancer, the true role of neoad‐
juvant and adjuvant chemotherapy for locally advanced bladder cancer remains unclear.
Neoadjuvant  chemotherapy  has  been  shown  to  help  for  debulking  and  facilitation  for
surgical resection at radical cystectomy. The overall survival benefit is unfortunately rela‐
tively low (< 9%) and treatment protocols are often not suitable in older patients with co‐
morbidities  and  decreased  renal  function  (Grossman,  Natale  et  al.  2003)  (Sonpavde,
Amiel et al.  2008) (2005).  Identification of responders versus non-responders to neoadju‐
vant chemotherapy seems to be of value for selection of patients to be treated with this
modality,  still  at  present -  robust and readily available markers predicting treatment re‐
sponse  are  lacking  (Rosenblatt,  Sherif  et  al.).  Adjuvant  chemotherapy  trials  have  been
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less clear, with at least a trend of improved disease-free survival in small series of statis‐
tically  underpowered trials  (Walz,  Shariat  et  al.  2008).  Thus,  other  treatment  modalities
are highly warranted for these patients.
Immunotherapy offers an appealing complement to traditional chemotherapy, with possi‐
ble long-term protection against tumor recurrences through immunological memory. Vac‐
cination trials have shown promising results in colorectal cancer patients (Hanna, Hoover
et  al.  2001)  (Mocellin,  Rossi  et  al.  2004)  (Karlsson,  Marits  et  al.).  Similar  studies  have
been performed in patients with malignant melanoma (Dudley,  Wunderlich et  al.  2005).
Adoptive  immunotherapy  with  the  collection  and  expansion  of  autologous  tumor-reac‐
tive  lymphocytes,  followed by re-transfusion to  the  patient,  has  been reported to  influ‐
ence  tumor  progression.  Another  approach,  using  a  combination  between  adoptive
immunotherapy and a retroviral gene therapy using specific malignant melanoma T cell
receptors, showed sustained levels of circulating, engineered cells at one year after infu‐
sion in two patients who both demonstrated objective regression of metastatic melanoma
lesions (Morgan, Dudley et al. 2006).
Due  to  promising  results  using  adoptive  immunotherapy,  our  interests  turned  to  blad‐
der  cancer,  as  few  new  cytotoxic  drugs  are  available.  This  review  provides  an  over‐
view  on  the  concept  of  sentinel  node  detection,  necessary  for  the  collection  and
expansion  of  autologous  tumor-reactive  lymphocytes  in  bladder  cancer  patients,  as  a
novel  adoptive immunotherapy.
2. Immunotherapy as cancer therapy
Over the past decade, interest has turned to other treatment concepts as novel cancer strat‐
egies than cytotoxic drugs. A variety of immunotherapeutic approaches have been tested in
order to stimulate the cellular and humoral arms of the immune system to induce tumor re‐
gression. Currently, the following treatment strategies seem most promising, including the
application of cytokines and adjuvant agents which modulate the cytokine response, cancer
vaccines designed to elicit cellular immune responses against tumor associated antigens
(TAAs), and monoclonal antibody drugs (Kusmartsev and Vieweg 2009).
Despite better understanding of the immune system only a few immunotherapeutic ap‐
proaches have received approval by the Federal Drug Agency (FDA) for treatment of uro‐
logical malignancies, such as the systemic administration of interleukin (IL-2) against
metastatic renal cell cancer (RCC) and the intravesical instillation of bacillus Calmette-Gué‐
rin (BCG) or interferon α for non-muscle-invasive bladder cancer. The cancer vaccine that
has received the most publicity and attention is undoubtedly Sipuleucel-T or Provenge®
(Lubaroff 2012). The vaccine was approved by the FDA in April 2010 for men with asympto‐
matic or minimal symptomatic castration resistant prostate cancer (CRPC).
Cancer vaccines are designed to stimulate expansion of the cellular arm of the immune sys‐
tem, mainly T cells and natural killer cells. Cytotoxic and helper T lymphocytes are consid‐
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ered the main immune effector cells, which in turn kill tumor cells via receptor mediated
interactions. Both cell types require activation by antigen presenting cells, such as dendritic
cells (DCs), to recognize and kill tumor cells in context with major histocompatibility com‐
plex (MHC) self-antigens. Natural killer cells, by contrast, kill rather non-specifically and
represent the first line of immunological defense against cancer and foreign pathogens.
Many vaccine approaches have shown high efficacy at triggering T-cell responses against
TAAs in tumor bearing animals—these approaches include vaccination with gene modified
tumor cells, antigen-loaded DCs, recombinant viral expression cassettes, and heat shock
proteins (Kusmartsev and Vieweg 2009).
Despite the fact that many immunologic approaches have moved from basic research in‐
to clinical trials, only a few showed clinical response and tumor regression. As the rates
of tumor regression has seldom exceeded 5 - 10%, with only a short duration of clinical
response,  the  efficacy  of  these  treatments  has  been  seriously  questioned  (Vieweg  and
Dannull 2005).  A possible explanation for the limited response of cancer vaccines lies in
the fact that new drugs must be initially studied in patients with advanced or metastatic
disease,  with  poor  survival  outcome.  Additionally,  the  immunogenicity  of  the  TAAs
used in reported vaccine formulations is  low, as most TAAs represent self-antigens that
are  overexpressed or  reactivated in cancer  cells  relative to  the non-cancerous cells  from
which they originated. Finally, tumors can evade the immune system (including the im‐
mune responses triggered by vaccination) through the induction of immune tolerance or
immune suppression (Kusmartsev and Vieweg 2009) (Gilboa 2004) (Rabinovich, Gabrilo‐
vich et al. 2007).
In times of economic uncertainties, cancer vaccine treatments are not without controversy.
The controversial issues that have been raised in using Sipuleucel-T include the high cost,
the modest improvement in overall survival (OS) and virtually an absence of change in time
to progression (Chambers and Neumann 2011) (Goozner 2011). Priced at $31,000 per treat‐
ment, with a usual course of three treatments, Sipuleucel-T is one of the most expensive can‐
cer therapies ever to hit the marketplace. Whether, health care providers can afford these
additional burden remains to be seen in the near future.
3. Immunotherapy in non-advanced urothelial carcinoma
Bladder  cancer  is  the  fifth  most  commonly  diagnosed  cancer  in  the  US  in  2012  (after
prostate, breast, lung, and colon cancers), with an estimated 73’510 new cases and 14’880
deaths  (2012).  Risk factors  for  developing bladder  cancer  include cigarette  smoking,  ex‐
posure  to  arsenic,  occupation  in  rubber  or  fossil  oil  industry,  and  schistosomiasis,  and
chronic inflammatory disease (Steineck, Plato et al.  1990).  Approximately 70% to 80% of
patients with newly diagnosed bladder cancer will present as noninvasive papillary tran‐
sitional-cell  carcinomas  (TCCs),  70%  of  which  will  recur,  and  10  –  20%  of  which  will
progress  and  invade  the  bladder  wall  (Babjuk,  Oosterlinck  et  al.  2012).  Those  who  do
present with superficial,  noninvasive bladder cancer can often be cured,  and those with
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deeply invasive disease can sometimes be cured by surgery, radiation therapy, or a com‐
bination of modalities that include chemotherapy.
According to the National Cancer Institute’s Surveillance Epidemiology and End Results
(SEER) registry, there has been a gradually increasing incidence of bladder cancer over the
past three decades (Kamel, Moore et al.). The incidence of muscle invasive tumors has re‐
mained stable over this time; however, the incidence of superficial, noninvasive bladder
cancer is rising.
Transurethral resection of bladder tumor (TURBT) is the standard initial therapeutic ap‐
proach for diagnosis and treatment of nonmuscle invasive bladder cancer (NMIBC) (Babjuk,
Oosterlinck et al. 2012) (Williams, Hoenig et al. 2010) (Brausi, Witjes et al.). However, al‐
though TURBT is an effective therapy, up to 45% of patients will experience tumor recur‐
rence within 1 year after TURBT alone (Hall, Chang et al. 2007). Additionally, a 3 to 15% risk
of tumor progression to muscle-invasive and/or metastatic cancer has been reported. Ac‐
cording to these figures TURBT alone is considered to be an insufficient treatment modality
in most patients. To overcome the limitations of TURBT alone, interest has turned towards
adjuvant intravesical treatment regimens since the early 1970s.
The difficulty in the management of  bladder cancer  comes from the inability  to  predict
which tumors will recur or progress. Current evidence suggest for the existence of mutu‐
ally  exclusive  molecular  pathways  to  tumorigenesis,  responsible  for  the  formation  of
papillary and invasive carcinomas, respectively (Wolff, Liang et al. 2005). The most com‐
mon genetic alterations in low grade papillary TCC are loss of heterozygosity of part or
all  of  chromosome 9 and activating mutations of  the fibroblast  growth factor receptor 3
(FGFR3)  (Cappellen,  De  Oliveira  et  al.  1999;  Cheng,  Huang et  al.  2002;  Bakkar,  Waller‐
and et al.  2003).  In contrast to the pathway responsible for the development of invasive
TCC which seems to start with dysplasia,  progress to carcinoma in situ,  followed by in‐
vasion of the lamina propria. The most frequent genetic alteration in dysplasia and carci‐
noma in  situ  is  mutation of  TP53,  followed by loss  of  heterozygosity  of  chromosome 9
(Burkhard, Markwalder et al.  1997; Orlow, LaRue et al.  1999; Sarkar, Julicher et al. 2000;
Hartmann,  Schlake et  al.  2002).  An important  marker  for  progression in  TCC is  loss  of
chromosome  8p,  which  occurs  in  approximately  60%  of  bladder  tumors  (Stoehr,  Wiss‐
mann et  al.  2004).  Global  trends of  increased genomic instability  and aberrant  methyla‐
tion  of  cytosine  residues  in  DNA  correlate  with  increased  tumor  invasion  and
progression (Dulaimi, Uzzo et al. 2004). This may partly explain why the incidence of su‐
perficial, noninvasive bladder cancer is rising (Kamel, Moore et al.).
4. Intravesical immunotherapy
Bacillus Calmette-Guerin (BCG) is the most commonly used first-line immunotherapeutic
agent for prophylaxis and treatment of carcinoma in situ and high-grade bladder cancer.
BCG has fundamentally changed the management of high risk nonmuscle invasive TCC,
particularly carcinoma in situ (CIS) (Babjuk, Oosterlinck et al.). The aim of adjuvant intra‐
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vesical immunotherapy is to avoid post-TURBT implantation of tumor cells, eradicate resid‐
ual cancer cells and delay tumor recurrence by local immunostimulation (Soloway,
Nissenkorn et al. 1983). The effect on cancer progression is unclear.
Other immunotherapeutic drugs include the interferons (IFN), interleukin (IL-2, IL-12), as
well as tumor necrosis factor (TNF), which have their place in BCG-refractory patients (Gla‐
zier, Bahnson et al. 1995; Magno, Melloni et al. 2002; Weiss, O'Donnell et al. 2003).
5. Bacillus Calmette-Guerin (BCG)
BCG is a live-attenuated vaccine, and until today considered to be the most effective in‐
travesical  treatment  for  carcinoma in  situ  and high grade stage Ta or  T1 TCC (Shelley,
Kynaston et al.  2001; Han and Pan 2006).  It  was developed by Albert Calmette and Ca‐
mille Guerin in 1921 at the Pasteur Institute in France by attenuating the bovine tubercu‐
lous  bacillus,  Mycobacterium  bovis  (Calmette  1931;  Herr  and  Morales  2008).  The
background of the antitumor properties of BCG is based on observational autopsy stud‐
ies in tuberculosis patients which had a lower frequency of various tumors (Pearl 1929).
Old et  al.  were  the  first  to  demonstrate  a  potential  benefit  using BCG in  infected mice
who showed increased resistance to challenge with transplantable tumors (Old, Clarke et
al.  1959).  Ten  years  later  Mathe  et  al.  reported  encouraging  results  with  BCG  as  adju‐
vant therapy for acute lymphoblastic leukemia (Mathe, Pouillart et al. 1969). In 1976, Mo‐
rales et al. were the first to report the successful use of BCG in the treatment of bladder
cancer (Morales, Eidinger et al. 1976).
The exact  mechanisms of  action and its  antitumor properties  of  BCG in  bladder  cancer
remains  to  be  elucidated.  However,  immediately  after  intravesical  instillation,  BCG  in‐
fects and is internalized into urothelial and bladder cancer cells via a fibronectin-depend‐
ent process mediated by integrins (Becich, Carroll et al. 1991; Kuroda, Brown et al. 1993).
Fibronectin  attachment  protein  (FAP)  mediates  BCG  attachment  to  bladder  cancer  cells
and  the  urothelial  wall  following  intravesical  instillation.  The  interaction  between  BCG
with  urothelial  cells  results  in  several  immunologically  changes,  including  induction  of
chemokines such as interleukin (IL)-1, IL-6, IL-8, IL-17 [18], GM-CSF, tumor necrosis fac‐
tor (TNF), and the up-regulation of intracellular adhesion molecule (ICAM)-1 (Alexandr‐
off,  Jackson  et  al.  1999;  Simons,  O'Donnell  et  al.  2008).  These  cytokines  are  considered
critical  for  cellular  assault  by causing tumor cells  to  display molecules  that  serve as  at‐
tachment anchors for  immune cells,  including neutrophils  and T lymphocytes,  and acti‐
vation  signals  such  as  ICAM-1,  fatty-acid  synthetase  (FAS),  CD40,  etc  (Alexandroff,
Jackson  et  al.  1999;  Wolff,  Liang  et  al.  2005).  The  importance  of  these  immunologic
changes can be partly assessed by the high level  of  IL-8 production which is  associated
with better clinical responses to BCG (Thalmann, Dewald et al. 1997; Thalmann, Sermier
et al. 2000).
After  weekly  intravesical  instillations  of  BCG,  a  variety  of  immune  cells  such  as  neu‐
trophils,  macrophages,  natural  killer  cells,  T  lymphocytes,  and NKT cells  are  constantly
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recruited.  Urinary samples  from patients  under  BCG instillation therapy contain  almost
seventy-five  percent  of  neutrophils,  five  to  ten  percent  of  macrophages  and  one  to
three  percent  of  NK cells  (De  Boer,  De  Jong  et  al.  1991).  The  neutrophils  secrete  cyto‐
kines  which  in  turn  activate  various  effector  cells.  To  achieve  an  immunologic  reaction
and  a  potential  therapeutic  effect  it  takes  five  to  six  BCG  instillations  (Prescott,  James
et  al.  1992)  (Jackson,  Alexandroff  et  al.  1995).
Potential effector cells responsible for tumor killing include MHC-nonrestricted cells such as
NK cells lymphokine-activated killer (LAK) cells, BCG-activated killer cells, CD-1-restricted
CD8+ T cells, gd T cells, NKT cells, neutrophils, macrophages, and MHC-restricted CD8+
and CD4+ T cells (Kitamura and Tsukamoto 2011). Of these cells, T lymphocytes are consid‐
ered to be the most effective effector cells responsible for eliminating cancer cells (Alexandr‐
off, Nicholson et al.). In a depletion study, both CD8+ and CD4+ T cells were found to be
essential for the successful antitumor effects of BCG (Ratliff, Ritchey et al. 1993).
According to  the  current  literature  at  least  four  meta-analyses  have shown that  TURBT
plus intravesical BCG is superior to TURBT alone for delaying time to first tumor recur‐
rence (Shelley, Kynaston et al.  2001; Bohle and Bock 2004; Shelley, Wilt  et al.  2004; Han
and Pan 2006). The largest meta-analysis by the EORTC reviewed data from 24 random‐
ized  trials  and  reported  that  the  progression  rate  in  the  group  TURBT  plus  BCG  was
9.8% vs. 13.8% in the control groups with a median follow-up of 2.5 years (maximum up
to 15 years) (Pawinski, Sylvester et al. 1996). Despite the fact that BCG may delay tumor
progression,  patients  are  still  at  risk  for  metastatic  or  muscle-invasive  disease.  This  has
been  highlighted  in  the  study  by  Lamm  et  al.  on  the  natural  history  of  untreated  CIS
with a progression rate to muscle-invasive disease in 54% (Lamm 1992).
Even with initial complete response after BCG treatment regimens, there is a continued risk
for tumor recurrence or the occurrence of new tumors on the long-term. Thus, according to
the risk assessment of the tumor lifelong surveillance is mandatory.
The administration of intravesical BCG, as well as its optimum dose and treatment schedule
remains under investigation. Until today the original treatment protocol by Morales et al. of
six instillations, once a week for six weeks, is still considered standard of care (Morales, Ei‐
dinger et al. 1976). Cystoscopy with urinary cytology is performed six weeks after comple‐
tion of BCG instillation to assess treatment response (Babjuk, Oosterlinck et al.).
6. Interferons (INFs)
IFNs are host-produced glycoproteins which act to mediate immune responses through antivi‐
ral, antiproliferative, and immuneregulatory activities (Williams, Hoenig et al.). In vitro stud‐
ies have shown that INFs have direct antitumor effects (Baron, Tyring et al. 1991). INF-α2b has
been the most extensively studied interferon as an intravesical agent, and it seems that the in vi‐
tro effect of antiproliferative activity on bladder cancer cells are also observed in vivo (Molto,
Alvarez-Mon et al. 1995). Several studies comparing the antitumor activity of INF-α2b com‐
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pared with BCG, demonstrated a clear inferiority regarding risk for recurrence or time to first
recurrence (Kalble, Beer et al. 1994; Portillo, Martin et al. 1997). For this reason, and the high
costs of INF-α2b, INF-α2b has been mainly used for salvage treatment protocols, as BCG fail‐
ure patients have a 15 - 20% complete response to INF-α2b at one year (Lam, Benson et al. 2003).
In order to determine whether mitomycin C followed by BCG vs. BCG plus IFN-a2b de‐
creased the intravesical recurrence rate, a randomized study could demonstrate that there is
no benefit by alternating IFN-a2b with BCG (Kaasinen, Rintala et al. 2000). Thus addition of
IFN-a to BCG does not seem to enhance the antitumor effects of BCG immunotherapy.
7. Future perspectives for intravesical treatments
Besides urgent need for tumor markers in bladder cancer patients to better detect recurrences,
attempts are under investigation for optimal drug delivery using intravesical treatments. Dif‐
ferent devices are currently under investigation such as thermochemotherapy and electromo‐
tive drug administration in non-muscle invasive bladder tumors. The idea behind these drug
delivery approaches is to temporarily breach the urothelium which in turn should lead in an in‐
creased accumulation of drugs in the bladder tissue. First results are encouraging using elec‐
tromotive  mitomycin  C  (eMMC)  instillations  in  patients  with  CIS,  with  a  statistically
significant, superior complete response rate at 6 months for eMMC (58%) compared to passive
MMC at the higher doses (31%) (Di Stasi, Giannantoni et al. 2003). The response rate of eMMC
approached that of BCG (64%). Local microwave hyperthermia (Synergo system) is another
technology being investigated in the treatment of bladder cancer. The Synergo system stimu‐
lates bladder wall hyperthermia through an energy delivering unit in the tip of a special cathe‐
ter equipped with internal thermocouples designed to maintain temperatures between 42 and
43°C. The aim is to increases cell-membrane permeability and by this way alter intracellular
drug trafficking and distribution (Moskovitz, Meyer et al. 2005). Whether these combined ap‐
proaches using thermal energy and intravesical agents will revolutionize the treatment of blad‐
der cancer remains to be seen in the future (Williams, Hoenig et al. 2010).
Another approach has been reported by Sharma et al. in a post TURBT adjuvant setting
(Sharma, Bajorin et al. 2008). The safety and immunogenicity of a recombinant NY-ESO-1
protein vaccine, which was administered with granulocyte macrophage colony-stimulating
factor and BCG as immunologic adjuvant was tested in a cohort of urothelial carcinoma pa‐
tients. Six patients met all eligibility criteria to receive the vaccination after TURBT for local‐
ized TCC. Tumor tissues were tested for NY-ESO-1 expression and patients, shown to have
NY-ESO-1 tumors, were vaccinated in the postoperative setting. Peripheral blood samples
were analyzed for vaccine-induced antibody and T-cell responses. NY-ESO-1-specific anti‐
body responses were induced in 5/6 patients whereas CD8 T-cell responses occurred in 1/6
patients and CD4 T-cell responses were found in 6/6 patients. This study demonstrates safe‐
ty and feasibility of the NY-ESO-1 recombinant protein in combination with BCG and gran‐
ulocyte macrophage colony-stimulating factor to induce predominantly antibody and CD4
T-cell responses in urothelial carcinoma patients. Induction of higher frequency of CD8 T-
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cell responses may be possible in clinical trials implementing NY-ESO-1 vaccination in com‐
bination with other immunomodulatory agents (Sharma, Bajorin et al. 2008).
8. Sentinel lymph node concept, detection and clinical implications
The sentinel node (SN) is defined as the first tumor-draining lymph node along the direct
drainage route from the tumor; in case of dissemination, it is considered being the first site
of metastasis. A tumor can have more than one primary sentinel node, due to different sec‐
tions of the tumor being drained. In a defined micro-anatomical drainage route, the first
node is called the first echelon SN followed by the second echelon SN, the third and so forth
(figure 1). Identification and subsequent pathologic examination of the SNs reflects the no‐
dal status of the remaining regional nodes. It is postulated that regional nodes in the vicini‐
ty, which are unconnected to the tumor draining routes, by definition cannot be or become
hosts of tumor dissemination. The concept of a sentinel node was first described 1960, in a
patient with cancer of the parotid gland (Gould, Winship et al. 1960). Detection of the SN
was further introduced in urology by Cabanas in 1977, aiming at improved accuracy in pen‐
ile carcinoma staging (Cabanas 1977). The SN technique is now established as a routine
method in malignant melanoma and breast cancer. SN detection is still experimental in uro‐
logic malignancies and is previously described in urinary bladder cancer (Sherif, De La
Torre et al. 2001) (Sherif, Garske et al. 2006) (Liedberg, Chebil et al. 2006), in prostate cancer
(Wawroschek, Vogt et al. 1999) (Jeschke, Nambirajan et al. 2005), in testicular cancer (Ohya‐
ma, Chiba et al. 2002) and in renal cell carcinoma (Sherif, Eriksson et al.) (Bex, Vermeeren et
al.). A further extension of the concept is in identification of Metinel nodes (MN), which are
defined as lymph nodes draining a metastatic site (Dahl, Karlsson et al. 2008 ). This might
have further implications in subsequent immunological therapies based on using tumor ex‐
tract as antigen source, due to the presence of intratumor heterogeneity both in primary tu‐
mors (Gerlinger, Rowan et al.) and the suggested clonal differentiation displayed in
metastatic sites (Malmstrom, Ren et al. 2002).
Various procedures entailing/techniques for sentinel node detection:
• Preoperative planar lymphoscintigraphy
• Preoperative planar lymphoscintigraphy in conjunction with SPECT/CT [single photone‐
mission CT (SPECT) with a low-dose CT]
• Intraoperative visual blue dye detection
• Intraoperative gamma probe/Geiger meter-detection
• Postoperative scintigraphy of main specimen with planar acquisition
In most centers one, two or three methods combined are considered being sufficient for the
everyday clinical praxis.
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Figure 1.
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9. T-cell function, including receptor and antigen recognition
The subset of lymphocytes called T cells mature in the thymus and are distinguished from
other lymphocytes (B-cells, NK-cells) by their T cell receptor (TCR) located on the cell sur‐
face. Different subsets of T cells display a variety of different functions:
• T helper cell (TH cells) [also known as CD4 cells]
• Cytotoxic T cells (CTLs or TC) [also known as CD8 cells]
• Memory T cells
◦ Central memory T cells (TCM cells)
◦ Effector memory T cells (TEM cells)
• Regulatory T cells (Treg cells)
◦ Naturally occurring Treg cells
◦ Adaptive Treg cells
• Natural killer T cells (NKT cells)
• γδ T cells (gamma delta T cells)
The origin of all T cells is the hematopoietic stem cells in the bone marrow. Immature thy‐
mocytes do not express any of the two markers CD4 or CD 8. During the development of the
thymocytes, they finally become either of the two major subsets followed by release to pe‐
ripheral tissues. Prior to the release, the TCR has developed on the surface through different
selection processes in the thymus, enabling the future mature T cell to interact with
MHC/HLA complexes and also to have attained a balanced reaction to self-antigens. The T
cells which exit the thymus are designated as mature naive T cells. The TCR is composed of
two separate peptide chains joined in a complex with CD3-proteins. When the TCR is acti‐
vated a number of processes take place finalizing in activation of the transcription factor
NFAT (Nuclear factor of activated T-cells). NFAT translocates to the nucleus of the T cell
and activates a number of genes as for instance IL-2, leading to growth, proliferation, and
differentiation of the T cell. The TCR requests co-stimulation of CD28 also expressed on the
T cell, for activation. In absence of interaction with CD28 when the T cell encounters APCs
(antigen presenting cells), the T cell will not proliferate and the end result will be anergy
and a suboptimal immunoresponse.
10. T-cell activation in lymph nodes
Animal models indicate that tumor antigensensitization of lymphocytes takes place in tu‐
mor draining lymph nodes (SNs and MNs), where tumor antigens are presented to T cells
by specialized APCs (Itano and Jenkins 2003). Naive T lymphocytes are activated through
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their TCRs by peptide–MHC complexes displayed on dendritic cells in secondary lymphoid
tissue (Jenkins, Khoruts et al. 2001). Upon activation, T cells undergo rapid proliferation, dif‐
ferentiating into effectors capable of migrating into various sites and of producing lympho‐
kines. A contraction phase then results in the elimination of the vast majority of T cells,
leaving behind a stable population of memory cells (Seder and Ahmed 2003).
11. Sentinel lymph node concept and immunology
In the sentinel nodes or metinel nodes, the antigen-presenting cells (most often dendritic
cells)  encounter tumor antigen, which is  digested to peptides.  The peptides are directed
to the class 2 pocket  and displayed on the cell  surface for recognition by CD4+ T cells.
Newly arrived T cells  are guided to the T-cell  zones of the node mainly by the chemo‐
kine CCL 21 through binding of the receptor CCR7 on the lymphocytes (Campbell, Bow‐
man et  al.  1998).  On encountering the APCs,  the naive T cells  are  specifically  activated
and undergo a clonal expansion.
Whereas effector memory cells are capable of executing immediate effector functions upon
antigen encounter, central memory cells home to lymph nodes, may provide a lifelong
source of new effector cells, both upon secondary stimulation and under the influence of ho‐
meostatic cytokines (Geginat, Sallusto et al. 2001) (Hammarlund, Lewis et al. 2003).
The tumor has its own line of defence when encountering an immunological assault in
which is known as tumor escape mechanisms; thus tumor cells may escape elimination by los‐
ing targeted antigens, rendering T-cells anergic by downregulation of costimulatory mole‐
cules, by inducing regulatory T-lymphocytes (T-regs), or by specifically deleting responding
T-lymphocytes (Staveley-O'Carroll, Sotomayor et al. 1998) (Woo, Yeh et al. 2002) (Engelhard,
Bullock et al. 2002) (Lee, Yee et al. 1999).
12. Adoptive immunotherapy using autologous T-cells in bladder cancer:
Results from the Karolinska University Hospital
Until now, only two pilot projects in humans describing immunotherapy using autologous
T-cells collected from tumor draining lymph nodes followed by cell culture and expansion,
have been published. The first one in advanced colon cancer and the second one in ad‐
vanced urothelial bladder cancer. In 2006 our group described the possibility and the techni‐
ques of identifying, harvesting, enhancing, refining and multiplying mainly T helper cells
(CD4+ Th1-lymphocytes) from draining sentinel lymph nodes in both colon cancer (Marits,
Karlsson et al. 2006) and in bladder cancer (Marits, Karlsson et al. 2006). From there, the next
step was taken and a treatment series of 16 patients with advanced colon cancer included
between 2003-2008, were described (Karlsson, Nilsson et al. 2008). The selected patients
were histopathologically classified as stage II, III or IV (AJCC criteria) tumors. The patients
were followed for 36 months on average (range 6–51 months) and monitored in accordance
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with the Swedish colorectal cancer follow-up protocol. The patients with distant metastases
(stage IV) responded to treatment, either with extended periods of stable disease (n = 4), par‐
tial response with diminished tumor burden (n = 1) or complete response with no detectable
remaining tumor (n = 4). The cumulative survival of the nine treated stage IV patients was
compared with all stage IV cases in the Stockholm region during the year of 2003. The me‐
dian survival of stage IV patients receiving immunotherapy was 2.6 years compared with
0.8 years median survival of the control group.
The same approach was used in urinary bladder cancer patients and the techniques and
methods were published 2010 in the first 12 patients in an ongoing pilot trial (Sherif, Hasan
et al. 2010). The preliminary results have so far included a total of 18 patients, in which 9
patients received intended treatment. Two of the nine treated patients showed objective re‐
sponses by RECIST criteria, and also exceptionally long overall survival (Sherif et al 2011).
Further evaluation and long-term follow-up results are necessary to assess the role of immu‐
notherapy in bladder cancer patients.
13. Future perspectives
Recent research has suggested that chemotherapy in the traditional form not only exerts its
effect on different moments in the cell cycle further leading to apoptosis, but also primarily
and secondarily plays a major role in tumor immunological events (Demaria, Volm et al.
2001) (Hong, Puaux et al.) (Ramakrishnan, Huang et al.). A challenging option would be to
combine neoadjuvant chemotherapy in high risk groups (non-responders and partial res‐
ponders to cisplatine combination therapies) with adjuvant immunotherapy in one form or
another. Hypothetically, neoadjuvant chemotherapy in urinary bladder cancer could be fol‐
lowed by sentinel node detection in conjunction with intended cystectomy. Primarily non-
responders (>pT0) could be offered inclusion in a trial entailing treatment with autologous
tumor-reactive lymphocytes.
14. Summary
According to the growing body of evidence in the understanding of molecular pathways
in tumor biology, other treatment modalities than surgery, chemotherapy and radiothera‐
py will  certainly increase our possibilities  to treat  various cancers.  Immunotherapy pro‐
vides the most exciting aspect for clinical research in the near future. As these treatments
are mainly applied to patients with advanced diseases it remains to be seen whether ear‐
ly treatment strategy immunotherapy protocols will  change the course of many diseases
in the near future. To date, however, there have been only a few published phase I or II
clinical trials of active immunotherapy for bladder cancer (table 1) (Sharma, Bajorin et al.
2008)  (Honma,  Kitamura  et  al.  2009)  (Sherif,  Hasan et  al.  2010)  (Malmstrom,  Loskog et
al.) (Matsumoto, Noguchi et al.).
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Author Treatmentprotocol Disease stage
Number of
patients Phase study Results Side effects
Sharma et al.
[2008]
NY-ESO-1
protein vaccine
+ CM-CSF + BCG
Adjuvant
treatment post-
TURBT
6 I Ag-specific
antibodies in
5/6 pts.,
CD8 T cell
response
in 1/6 Pts,
CD4 T cell
response in 6/6
pts.
Only mild
injection site
reactions
Honma et al.
[2009]
Survivin-2B80-8
8 peptide
vaccination
Advanced TCC 9 I CD8 T cell
response in
5/9 pts.,
tumor
reduction
in 1/9 pts.
No side effects
Sherif et al.
[2010]
Reinfusion of
autologous T-
helper
cells
T2-T4 N1-2
M0-1
bladder cancer
12 I Feasible in 6/12
Pts,
technical failure
in 6/12
Pts,
No severe
adverse events
Malmström et
al.
[2010]
Adenoviral
vector
expressing
CD40
ligand
(intravesical)
Muscle-invasive
TCC scheduled
for
cystectomy
(phase I),
Ta disease
(phase II)
8 I/II Enhancement
of T cell
infiltration and
IFN-γ
production,
reduction of
circulating
regulatory T-
cells
No severe
adverse events,
minor local pain
Matsumoto et
al.
[2011]
Personalized
peptide
vaccine
Advanced TCC
(MVAC failure)
10 I 1 CR, 1 PR, 2 SD,
PFS 3.0 months,
OS 8.9 months
No severe
adverse events
MVAC: methotrexate,vinblastine, adriamycin and cisplatin; CR: complete response; PR: partial response; SD: stable dis‐
ease, PFS: progression-free survival; OS: overall survival
Table 1. Present phase I and II clinical trials of active immunotherapy in bladder cancer
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